Maciej Nowacki1, Mohammad Alyami2, Laurent Villeneuve3, Frederic Mercier4, Martin Hubner5, Wouter Willaert6, Wim Ceelen6, Marc Reymond7, Denis Pezet8, Catherine Arvieux9, Vladimir Khomyakov10, Laura Lay11, Sergio Gianni12, Wojciech Zegarski13, Naoual Bakrin14, Olivier Glehen14. 1. Chair and Department of Surgical Oncology, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital in Bydgoszcz, Bydgoszcz, Poland. Electronic address: maciej.s.nowacki@gmail.com. 2. Department of Digestive Surgery, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; EMR 3738, Lyon 1 University, Lyon, France; RENAPE, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France; King Salman Scholarship Program, Saudi Arabian Cultural Bureau, Paris, France. 3. Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France; EMR 3738, Lyon 1 University, Lyon, France; RENAPE, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France. 4. Department of Digestive Surgery, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; RENAPE, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France. 5. Department of Visceral Surgery, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. 6. Department of Gastrointestinal Surgery, Ghent University Hospital, Ghent, Belgium. 7. Department of Surgery, University of Tübingen, Tübingen, Germany. 8. Chirurgie et Oncologie Digestive, Université Clermont Auvergne Clermont-Ferrand, France. 9. Digestive and Emergency Surgery, UGA-Université Grenoble Alpes, Grenoble, France. 10. Moscow Research Oncological Institute n.a. P.A. Herzen, Thoracoabdominal, Moscow, Russian Federation. 11. Department of Gynecology Surgical Area at the Institute of Oncology A. H. Roffo, University of Buenos Aires, Buenos Aires, Argentina. 12. Instituto de Oncología Ángel Roffo, Buenos Aires, Argentina. 13. Chair and Department of Surgical Oncology, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital in Bydgoszcz, Bydgoszcz, Poland. 14. Department of Digestive Surgery, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; EMR 3738, Lyon 1 University, Lyon, France; RENAPE, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.
Abstract
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method offered in selected patients suffering from non-resectable peritoneal carcinomatosis (PC). As reported experience is still limited, we conducted a survey among active PIPAC centers aiming to report their technical approach and clinical findings. METHODS: An online survey was sent to active PIPAC centers worldwide. The questionnaire consisted of 34 closed questions and was conducted over a period of 3 months beginning in March 2017. RESULTS: Nine out of 15 contacted centers completed the questionnaire totaling 832 PIPAC procedures in 349 patients. Most common indications for PIPAC were PC from gastric, ovarian and colorectal origin. The mean time between each PIPAC procedure was 6-8 weeks. Seven of nine (77.8%) centers evaluate the PCI at every PIPAC procedure. At least four tissue samples for histopathology analysis were retrieved in 5 (55.6%). All centers (100%) use the same chemotherapy protocol: oxaliplatin at a dosage of 92mg/m2 for PC of colorectal origin and a combination of cisplatin and doxorubicin at a dosage of 7.5mg/m2 and 1.5mg/m2, respectively, for other types of PC. Eight centers (88.9%) perform routine radiological evaluation before first PIPAC and after third PIPAC. CONCLUSION: These data confirm that PIPAC procedures are homogeneously performed in established centers. Standardization of the procedure will facilitate future international multicenter prospective clinical trials.
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method offered in selected patients suffering from non-resectable peritoneal carcinomatosis (PC). As reported experience is still limited, we conducted a survey among active PIPAC centers aiming to report their technical approach and clinical findings. METHODS: An online survey was sent to active PIPAC centers worldwide. The questionnaire consisted of 34 closed questions and was conducted over a period of 3 months beginning in March 2017. RESULTS: Nine out of 15 contacted centers completed the questionnaire totaling 832 PIPAC procedures in 349 patients. Most common indications for PIPAC were PC from gastric, ovarian and colorectal origin. The mean time between each PIPAC procedure was 6-8 weeks. Seven of nine (77.8%) centers evaluate the PCI at every PIPAC procedure. At least four tissue samples for histopathology analysis were retrieved in 5 (55.6%). All centers (100%) use the same chemotherapy protocol: oxaliplatin at a dosage of 92mg/m2 for PC of colorectal origin and a combination of cisplatin and doxorubicin at a dosage of 7.5mg/m2 and 1.5mg/m2, respectively, for other types of PC. Eight centers (88.9%) perform routine radiological evaluation before first PIPAC and after third PIPAC. CONCLUSION: These data confirm that PIPAC procedures are homogeneously performed in established centers. Standardization of the procedure will facilitate future international multicenter prospective clinical trials.
Authors: Koen P Rovers; Emma C E Wassenaar; Robin J Lurvink; Geert-Jan M Creemers; Jacobus W A Burger; Maartje Los; Clément J R Huysentruyt; Gesina van Lijnschoten; Joost Nederend; Max J Lahaye; Maarten J Deenen; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh Journal: Ann Surg Oncol Date: 2021-02-05 Impact factor: 5.344
Authors: S Bremholm Ellebæk; M Graversen; S Detlefsen; L Lundell; C W Fristrup; P Pfeiffer; M B Mortensen Journal: Clin Exp Metastasis Date: 2020-01-30 Impact factor: 5.150
Authors: Robin J Lurvink; Koen P Rovers; Simon W Nienhuijs; Geert-Jan Creemers; Jacobus W A Burger; Ignace H J de Hingh Journal: J Gastrointest Oncol Date: 2021-04
Authors: Linda Feldbrügge; Felix Gronau; Andreas Brandl; Timo Alexander Auer; Alan Oeff; Peter Thuss-Patience; Johann Pratschke; Beate Rau Journal: Front Oncol Date: 2021-04-12 Impact factor: 6.244
Authors: Daniel Clerc; Martin Hübner; K R Ashwin; S P Somashekhar; Beate Rau; Wim Ceelen; Wouter Willaert; Naoual Bakrin; Nathalie Laplace; Mohammed Al Hosni; Edgar Luis Garcia Lozcano; Sebastian Blaj; Pompiliu Piso; Andrea Di Giorgio; Giuseppe Vizzelli; Cécile Brigand; Jean-Baptiste Delhorme; Amandine Klipfel; Rami Archid; Giorgi Nadiradze; Marc A Reymond; Olivia Sgarbura Journal: Pleura Peritoneum Date: 2021-02-12